Selective miRNA Modulation Fails to Activate HIV Replication in In Vitro Latency Models
HIV remains incurable because of viral persistence in latent reservoirs that are inaccessible to antiretroviral therapy. A potential curative strategy is to reactivate viral gene expression in latently infected cells. However, no drug so far has proven to be successful in vivo in reducing the reserv...
Main Authors: | María Rosa López-Huertas, Matías Morín, Nadia Madrid-Elena, Carolina Gutiérrez, Laura Jiménez-Tormo, Javier Santoyo, Francisco Sanz-Rodríguez, Miguel Ángel Moreno Pelayo, Laura García Bermejo, Santiago Moreno |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253119301696 |
Similar Items
-
Selective miRNA inhibition in CD8+ cytotoxic T lymphocytes enhances HIV-1 specific cytotoxic responses
by: Nadia Madrid-Elena, et al.
Published: (2022-09-01) -
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017-05-01) -
Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs
by: Nicole L. Diggins, et al.
Published: (2021-02-01) -
Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019-12-01) -
The role of miR-29a in HIV-1 replication and latency
by: Giacomo Frattari, et al.
Published: (2017-10-01)